17 alpha-hydroxyprogesterone caproate has been researched along with Preterm Birth in 228 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (11.40) | 29.6817 |
| 2010's | 146 (64.04) | 24.3611 |
| 2020's | 56 (24.56) | 2.80 |
| Authors | Studies |
|---|---|
| Alavi, A; Atighpoor, F; Ranjbar, A; Zare, S | 1 |
| Ntozini, R; Prendergast, AJ | 1 |
| Chomba, E; Cole, SR; Freeman, BL; Goldenberg, RL; Kasaro, MP; Mbewe, FM; Muyangwa, D; Mwape, H; Peterson, M; Phiri, WM; Price, JT; Rouse, DJ; Saha, PT; Sindano, N; Smithmyer, ME; Stringer, JSA; Vwalika, B | 1 |
| Bowman, ME; Herrera, CL; McIntire, DD; Nelson, DB; Smith, R | 1 |
| Caritis, SN; Hauspurg, A; Megli, CJ; Venkataramanan, R | 1 |
| Boelig, RC; Garcia, SM; Kellom, KS; Matone, M; Wang, X | 1 |
| Donohue, JM; Dusetzina, SB; Gavulic, KA; Sachs, RE | 1 |
| Finneran, MM; Frey, HA; Hade, EM; Iams, JD; Landon, MB; Lynch, CD; Waickman, C | 1 |
| Deng, Z; Lu, D | 1 |
| Backley, S; Berghella, V; Boelig, RC; Frey, H; Gimovsky, AC; Schoen, CN; Springel, E | 1 |
| Alizadeh, F; Mahmoudinia, M; Mirteimoori, M; Niroumand, S; Pourali, L | 1 |
| Biron-Shental, T; Cohen, G; Miller, N; Moran, R; Ovadia, M; Schreiber, H; Shavit, M; Shechter-Maor, G; Weitzner, O; Yagur, Y | 1 |
| Berghella, V; Boelig, RC; Gragnano, E; Locci, M; Saccone, G | 1 |
| Dresang, L; Vellardita, L | 1 |
| Beam, AL; Hakim, JB; Hart, JM; Wylie, BJ | 1 |
| Al-Lami, RA | 1 |
| Smith, MM; Swamy, GK; Truong, T; Weber, JM; Wheeler, SM | 1 |
| Cole, SR; Conner, MG; Freeman, BL; Kasaro, MP; Mabula-Bwalya, CM; Price, JT; Sebastião, YV; Stringer, EM; Stringer, JSA; Vwalika, B | 1 |
| Boelig, RC | 1 |
| Alshabi, A; Bastian, JR; Caritis, S; Chaphekar, N; Shaik, IH; Vasudevan, V; Venkataramanan, R; Zhao, W | 1 |
| Harris, E | 1 |
| Caritis, SN; Chauhan, SP; Clark, S; Costantine, MM; Kiley, JW; Metz, TD; Stika, CS; Venkataramanan, R | 1 |
| Blumenfeld, YJ; Datoc, IA; Druzin, ML; El-Sayed, YY; Girsen, AI; Kan, P; Leonard, SA; Shaw, GM; Stevenson, DK; Tsur, A | 1 |
| Heyborne, K | 1 |
| Adams Waldorf, KM; Baxter, C; Coler, B; Crary, I; Huebner, EM; Marcell, L; Rutz, S | 1 |
| Affan, M; Ilyas, E | 1 |
| Cerrillos, L; Fernandez-Macias, R; Figueras, F; Martinez-Portilla, RJ; Palacio, M | 1 |
| Baker, J; Biggio, JR; Birch, R; Blackwell, SC; Chauhan, SP; Das, AF; Duncan, M; Gudeman, J; Gyamfi-Bannerman, C; Hughes, BL; Jozwiakowski, MJ; Krop, J; Louis, JM; Manuck, TA; Miller, HS; Nielsen, P; Pekarev, O; Reznichenko, GI; Reznichenko, NY; Saade, GR; Tatarova, N; Williams, L; Yuzko, OM | 1 |
| Ali, MK; Attyia, KM; Shaamash, AH | 1 |
| Owen, J; Szychowski, JM; Williams, BN; Wood, SL | 1 |
| Rubin, R | 1 |
| Godlewski, BJ; Harrod, CS; King, VJ; Sobolik, LI | 1 |
| Gandell, DL; Gudeman, JL; Randell, MD | 1 |
| Das, AF; Saade, GR; Sibai, B | 1 |
| Liu, LY; Miller, ES; Roy, A; Sakowicz, A; Yee, LM | 1 |
| Leveno, KJ; McIntire, DD; Nelson, DB | 4 |
| Das, AF; Gudeman, J; Saade, GR; Sibai, B | 1 |
| Chang, CY; Guo, J; Joffe, HV; Johnson, LL; Nguyen, CP; Wesley, B | 1 |
| Greene, MF; Harrington, D; Klebanoff, MA | 1 |
| Caritis, SN; Combs, CA; Lemon, L; Megli, C; Venkataramanan, R | 1 |
| Al-Kouatly, HB; Berghella, V; Boelig, RC; Greenberg, V; Valcarcel, B; Ward, A | 1 |
| Babbar, S; Edwards, AM; Forinash, AB; Lowry, SA; Mikovich, S | 1 |
| Armbruster, R; Boerrigter, A; Childress, K; Franklin, BHK; Massa, K; Sauer, M; Tomlinson, T; Vricella, LK | 1 |
| Hesson, AM; Langen, ES; Pitts, DS | 1 |
| Anders, NM; Bailey, A; Bensouda, S; Burd, I; DeLong, K; Dimitrion, P; Ensign, LM; Hanes, J; Laney, V; Li, G; Mahendroo, M; Mesiano, S; Ortiz, JI; Scardina, M; Wagner, G; Yu, J; Zierden, HC | 1 |
| Abdalla, A; Dotters-Katz, SK; Hynes, JS; Manuck, TA; Schwartz, AR | 1 |
| Ananth, CV; D'Alton, ME; Friedman, AM; Gomez, D; Gyamfi-Bannerman, C; Huang, Y; Schuster, M; Wright, JD | 1 |
| Carter, DM; DeLong, K; Ensign, LM; Shapiro, RL; Zierden, HC | 1 |
| Eswaran, H; Ghahremani, T; Magann, EF; McCoy, H; Ounpraseuth, S; Phillips, A; Whittington, J | 1 |
| Ajao, A; Chang, C; Cosgrove, A; Kolonoski, J; Moeny, D; Nguyen, CP; Shinde, M; Tsai, HT; Woods, CM | 1 |
| Rascati, KL; Zhang, S | 1 |
| Fujimori, K; Fukuda, T; Kyozuka, H; Murata, T; Yamaguchi, A; Yasuda, S | 1 |
| Lolier, M; Miller, RO; Wagner, CK; Wood, RI | 1 |
| Fahrenkopf, A; Li, G; Wagner, CK; Wood, RI | 1 |
| Eke, AC; Hesson, A; Oler, E | 1 |
| Owens, L; Prager, S | 1 |
| Bustos, ML; Caritis, SN; Carpenter, MW; Iams, JD; Jablonski, KA; Manuck, T; Mercer, BM; Peaceman, AM; Ramin, SM; Reddy, UM; Rouse, DJ; Sciscione, A; Sorokin, Y; Varner, MW; Wapner, RJ | 1 |
| Dotters-Katz, SK; Goodnight, WH; Manuck, TA; Ning, A; Vladutiu, CJ | 1 |
| Abramovici, AR; Biggio, JR; Harper, LM; Jauk, VC; Kuper, SG; Tita, AT | 1 |
| Grant, JH; Manuck, TA; Vladutiu, CJ | 1 |
| Acaia, B; Benedetto, C; Di Tommaso, M; DʼAmico, R; Facchinetti, F; Locatelli, A; Marozio, L; Pignatti, L; Spitaleri, M; Vergani, P; Vicini, R; Zaina, B | 1 |
| Anguiano, RH; Bobowski, C; Mastrogiannis, D; Milikhiker, N; Stone, RH | 1 |
| Apostolakis-Kyrus, K; Gomez, LM; Merriman, AL; Samson, FD; Tate, DL | 1 |
| O'Brien, JM | 6 |
| Fang, D; Garfield, RE; Kuon, R; Moreno, M; Xia, H | 1 |
| Greenwood, BC; Hydery, T; Jeffrey, PL; Kunte, PS; Lenz, K; Mauro, RP; Price, MK; Takeshita, M | 1 |
| Manuck, TA | 1 |
| Beam, AL; Fried, I; Kohane, IS; Palmer, NP | 1 |
| Kumar, D; Lockwood, CJ; Mansour, JM; Mercer, BM; Mesiano, S; Moore, JJ; Moore, RM; Schatz, F | 1 |
| Gee, RE; Karas, LO; Kuy, S | 1 |
| Ahmed, M; Caritis, SN; Chang, J; D'Alton, ME; Famy, AS; Haas, DM; Haneline, LA; Hankins, G; Harris, J; Hebert, M; Ren, Z; Simhan, H; Venkataramanan, R; Yorio, P | 1 |
| Dexter, S; Zelig, C | 1 |
| Fry, RC; Manuck, TA; Martin, EM; Smeester, L; Smith, C; Tomlinson, MS; Varner, MW | 1 |
| Caritis, SN; Hauspurg, A; Lemon, LS; Serra, AE; Sharma, S; Venkataramanan, R | 1 |
| Blumenfeld, YJ; El-Sayed, YY; Langen, ES; Lyell, DJ; Sherwin, K; Sit, A | 1 |
| Chauhan, SP; Easter, SR; Little, SE; Mendez-Figueroa, H; Robinson, JN | 1 |
| Bagga, R; Bansal, P; Kalra, J; Kumar, P; Shambhavi, S | 1 |
| Berghella, V; Di Sarno, R; Mokhtari, N; Parker, P; Quist-Nelson, J; Saccone, G | 1 |
| Frappaolo, A; Vadnais, M | 1 |
| Biggio, JR; Birch, R; Blackwell, SC; Chauhan, SP; Das, AF; Gyamfi-Bannerman, C; Hughes, BL; Jozwiakowski, MJ; Louis, JM; Manuck, T; Miller, HS | 1 |
| Mesiano, S; Weatherborn, M | 1 |
| Benatar, S; Cheeks, M; Courtot, B; Cross-Barnet, C; Hill, I; Johnston, E | 1 |
| Caritis, SN; Hauspurg, A; Lemon, L; Venkataramanan, R | 1 |
| Bennett, PR; Sykes, L | 1 |
| Bofill, JA; Collier, CH; Morrison, JC; Pearson, M; Shwayder, JM | 1 |
| Di Sarno, R; Raffone, A; Saccone, G | 1 |
| Eke, AC; Graham, EM; Sheffield, J | 2 |
| Jackson, J; Leziak, K; Miller, ES; Yee, LM | 1 |
| Beyene, J; Jarde, A; Lutsiv, O; McDonald, SD | 1 |
| Berhie, SH; Bryant, AS; Riley, LE | 1 |
| Urato, AC | 1 |
| Baker, DA; Demishev, M; Garry, DJ; Kocis, C; Peresleni, T; Persad, MD | 1 |
| DeNoble, A; Janko, M; Lantos, P; Swamy, G; Weaver, K; Wheeler, S; Wynn, C | 1 |
| DeNoble, AE; Swamy, GK; Weaver, KE; Wheeler, SM; Wynn, CE | 1 |
| Chomba, E; Cole, SR; Freeman, BL; Goldenberg, RL; Mbewe, FM; Mofenson, LM; Mulenga, HB; Price, JT; Rouse, DJ; Stringer, JSA; Vwalika, B; Winston, J | 1 |
| Kalata, M; Swarr, V; Teter, K; Wagner, L; Witzeman, K | 1 |
| Cahill, AG; Carter, EB; Macones, GA; Olsen, MA; Stout, MJ; Tuuli, MG | 1 |
| Byrns, MC | 1 |
| Deeks, ED; Hines, M; Lyseng-Williamson, KA | 1 |
| Durnwald, CP | 1 |
| Azimi, S; Bretelle, F; Capelle, M; Connan, L; Deruelle, P; Langer, B; Laurent, Y; Mantel, A; Perrotin, F; Porcher, R; Rozenberg, P; Senat, MV; Vayssière, C; Winer, N | 1 |
| Anton, L; Elovitz, MA; Maubert, M; Nold, C; Yellon, S | 1 |
| Bettinger, J; Caritis, SN; Venkataramanan, R; Zhao, Y | 1 |
| Driggers, RW; Istwan, N; Rhea, D; Singh, J; Timofeev, J | 1 |
| Fan-Havard, P; Franco, A; Prescott, GM; Schmouder, VM | 1 |
| Romero, R; Stanczyk, FZ | 1 |
| Ananth, CV; Brubaker, S; Fuchs, K; Gyamfi-Bannerman, C; Moni, S; Nhan-Chang, CL; Pessel, C; Vink, J; Zork, N | 1 |
| Caritis, SN; Carpenter, MW; Grobman, WA; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, JM; Varner, MW; Venkataramanan, R; Wapner, RJ | 1 |
| Iams, JD; Lynch, CD; Markham, KB; Walker, H | 1 |
| Briery, CM; Chauhan, SP; Klauser, CK; Magann, EF; Martin, RW; Morrison, JC | 1 |
| Combs, CA; Das, A; Garite, TJ; Maurel, K | 1 |
| Esplin, MS; Jackson, GM; Jorde, L; Manuck, TA; Moore, B; Varner, MW; Watkins, WS; Yandell, M | 1 |
| Haram, K; Morrison, JC; Mortensen, JH | 1 |
| Berghella, V; Gimovsky, A | 1 |
| Aboulghar, MA; Aboulghar, MM; Amin, YM; Awwad, J; Briery, CM; Cam, C; Caritis, SN; Çetingöz, E; Combs, CA; Fonseca, EB; Garite, T; Groenwold, RH; Karateke, A; Kwee, A; Lim, AC; Magann, EF; Maurel, K; Meseguer, J; Mol, BW; Moons, KG; Morrison, JC; Nassar, AH; Nicolaides, KH; Norman, JE; Perales, A; Rode, L; Ross, S; Rouse, DJ; Schuit, E; Serra, V; Stock, S; Tabor, A; Thom, EA; Usta, IM; Vayssiere, C; Wood, S; Worda, K; Zuithoff, NP | 1 |
| Awwad, J; Ghazeeri, G; Hayek, S; Nassar, AH; Saasouh, W; Succar, J; Usta, IM; Yacoub, N | 1 |
| Caritis, S; Feghali, M; Venkataramanan, R | 1 |
| Conde-Agudelo, A; Romero, R | 1 |
| Egerman, R; Istwan, N; Ramsey, R; Rhea, D; Stanziano, G | 1 |
| Azimi, S; Bohec, C; Bretelle, F; Capelle, M; Connan, L; Deruelle, P; Langer, B; Perrotin, F; Porcher, R; Rozenberg, P; Senat, MV; Vayssière, C; Winer, N | 1 |
| Berghella, V; Caughey, AB; Iams, JD; Schoen, CN; Tabbah, S | 1 |
| Block-Abraham, D; Gee, RE; Orsulak, MK | 1 |
| Co, AL; Hade, EM; Iams, JD; Walker, HC | 1 |
| Owen, J; Subramaniam, A; Wetta, LL | 1 |
| Hughes, BL; Lopes, V; Mainiero, AD; Rouse, DJ | 1 |
| Chaemsaithong, P; Furcron, AE; Gomez-Lopez, N; Hassan, SS; Mahajan, A; Plazyo, O; Romero, R; Unkel, R; Xu, Y | 1 |
| Allshouse, AA; Carey, JC; Heyborne, KD | 1 |
| Ananth, CV; Hanna, N; Keeler, SM; Kiefer, DG; Peltier, MR; Rust, O; Vintzileos, AM | 1 |
| Lewis, DF; O'Brien, JM | 1 |
| Caritis, SN; Combs, CA; Garite, TJ; Lim, AC; Maurel, K; Mol, B; Rouse, D; Schuit, E; Thom, E; Tita, AT | 1 |
| Abdul Karim, AK; Lim, PS; Ng, BK; Ng, KS; Omar, MH; Shafiee, MN | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Zhang, H | 1 |
| Goodnight, W | 1 |
| Manuck, T; Menard, MK; Ollendorff, A; Stringer, EM; Stringer, JS; Verbiest, S; Vladutiu, CJ | 1 |
| Bolden, JR; Liu, LY; Miller, ES; Sakowicz, A; Yee, LM | 1 |
| Owen, J; Wood, SL | 1 |
| Caritis, SN; Feghali, MN; Grobman, WA; Rouse, DJ | 1 |
| Ahn, KH; Bae, NY; Cho, GJ; Hong, SC; Jee, HJ; Kim, HJ; Lee, EH; Lee, JS; Oh, MJ | 1 |
| Elimian, A; Escobedo, MB; Goodman, JR; Knudtson, E; Smith, K; Williams, M | 1 |
| Esplin, MS; Fry, RC; Manuck, TA; Stoddard, GJ; Varner, MW | 1 |
| Allshouse, AA; Heyborne, KD | 1 |
| Bahrami, E; Bahrami, MA; Berghella, V; Chaman-Ara, K; Elimian, A; Khalifeh, A; Saccone, G | 1 |
| Heyborne, KD | 1 |
| Bayesh, S; Esmailzadeh, A; Heidari, R; Pirjani, R; Rahimi-Foroushani, A | 1 |
| Batra, P; Menard, MK; Stringer, EM; Stringer, JSA; Vladutiu, CJ | 1 |
| Haidar, ZA; Hosseini Nasab, S; Moussa, HN; Sibai, BM | 1 |
| Batra, P; Hirai, A; Lee, V; Lu, M; Selk, S | 1 |
| Berghella, V; Owen, J; Szychowski, JM | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Jorde, LB; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Watkins, WS; Yandell, M; Zhan, H | 1 |
| Gard, J; Leveno, KJ; McDonald, J; McIntire, DD; Nelson, DB; Turrichi, P | 1 |
| Barhan, S; Desch, C; Duke, J; Istwan, N; Po, W; Rhea, D; Stanziano, G; Ventolini, G | 1 |
| Istwan, N; Newman, R; Rhea, D; Rittenberg, C; Stanziano, G; Sullivan, S | 2 |
| Calda, P | 1 |
| Anderson, G; Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Mercer, BM; Momirova, V; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thorp, J; Varner, M; Wapner, RJ | 1 |
| Bornstein, E; Keeler, SM; Proudfit, CL | 1 |
| Barton, JR; Ho, SJ; Istwan, NB; O'Brien, JM; Rhea, DJ; Stanziano, GJ | 1 |
| Briery, CM; Chauhan, SP; Klauser, CK; Magann, EF; Martin, RW; Morrison, JC; Veillon, EW | 1 |
| Durnwald, CP; Iams, JD; Lynch, CD; Walker, H | 1 |
| Anderson, GD; Caritis, SN; Carpenter, MW; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, J; Varner, MW; Wapner, RJ | 1 |
| Caritis, SN; Dorko, K; Ellis, EC; Mattison, DR; Sharma, S; Strom, SC; Venkataramanan, R; Zhang, S | 1 |
| Fox, NS; Istwan, NB; Klauser, CK; Rebarber, A; Rhea, DJ; Saltzman, DH; Stanziano, GJ | 1 |
| Berghella, V; Figueroa, D; Guzman, ER; Hankins, GD; Iams, JD; Owen, J; Perez-Delboy, A; Sheffield, JS; Szychowski, JM; Wing, DA | 1 |
| Caritis, SN; Carpenter, MW; Durnwald, CP; Harper, M; Lo, J; Malone, FD; Mercer, BM; Momirova, V; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW | 1 |
| Facchinetti, F | 1 |
| House, KM; Krueger, CR; Lucas, B; Mason, MV; Poole-Yaeger, A | 1 |
| Foglia, LM; Ippolito, DL; Napolitano, PG; Stallings, JD; Zelig, CM | 1 |
| Combs, CA; Das, A; Garite, T; Maurel, K; Porto, M | 1 |
| Berghella, V; Mackeen, AD; Rafael, TJ | 1 |
| Armstrong, J | 2 |
| Cunningham, FG; Silver, RM | 1 |
| Cohen, AW; Copel, JA; Macones, GA; Menard, MK; Riley, L; Saade, GR | 1 |
| Adamczak, JE; Bastek, JA; Elovitz, MA; Hoffman, S; Srinivas, SK | 1 |
| Khadem, N; Mohajeri, T; Saghafi, N; Shakeri, MT | 1 |
| Hall, NR | 1 |
| Caritis, SN; Dombrowski, MP; Durnwald, CP; Lai, Y; Manuck, TA; Meis, PJ; Mercer, BM; Ramin, SM; Rouse, DJ; Sibai, B; Spong, CY; Wapner, RJ | 1 |
| Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R | 1 |
| Dearmond, C; Henderson, ZT; How, H; Sibai, B; Wolfe, K | 1 |
| Hansen, KA | 1 |
| Chin, JR; Heine, RP; Murtha, AP; Ransom, CE; Roeder, HA; Sinclair, TR | 1 |
| Alexander, J; Coleman, S; Istwan, N; Wallace, L | 1 |
| Bernardus, RE; Bloemenkamp, K; Bruinse, HW; Duvekot, JJ; Erwich, JJHM; Groenwold, RHH; Hasaart, THM; Hummel, P; Kars, MM; Kwee, A; Lim, AC; Mol, BWJ; Papatsonis, D; Porath, MM; Schuit, E; Spaanderman, ME; van Eyck, J; van Oirschot, CM; van Pampus, MG; Willekes, C; Wilpshaar, J | 1 |
| Deeks, ED | 1 |
| Barton, JR; Barton, LA; Desch, CN; Istwan, NB; Rhea, DJ; Sibai, BM | 1 |
| Cordova, YC; Desch, CN; Gonzalez-Quintero, VH; Istwan, NB; Marimon, A; Rhea, DJ; Romary, LM; Stanziano, GJ; Tudela, F | 1 |
| Klinger, G; Merlob, P; Stahl, B | 1 |
| Gupta, S; Roman, AS | 1 |
| Chollet, JL; Jozwiakowski, MJ | 1 |
| Azimi, S; Azria, E; Bohec, C; Capelle, M; Chauveaud, A; Connan, L; Deruelle, P; Desbrière, R; Langer, B; Mantel, A; Perrotin, F; Porcher, R; Rozenberg, P; Vayssière, C; Winer, N | 1 |
| Istwan, N; Lucas, B; Mason, M; Poole-Yaeger, A; Rhea, D; Stanziano, G | 1 |
| Kuehn, BM | 1 |
| Istwan, NB; Palmer, B; Sibai, BM; Stanziano, GJ | 1 |
| Fox, NS; Peress, D; Rebarber, A; Romero, J; Saltzman, DH; Schwartz, R | 1 |
| Berghella, V; Guzman, ER; Hankins, G; Iams, JD; Owen, J; Perez-Delboy, A; Sheffield, JS; Szychowski, JM; Wing, DA | 1 |
| Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Simhan, HN; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Zhao, Y | 1 |
| Bruinse, HW; de Graaf, IM; Hasaart, TH; Hummel, P; Kleiverda, G; Lim, AC; Mol, BW; Papatsonis, D; Porath, MM; Schuit, E; van Eyck, J; van Ginkel, AA; van Oirschot, CM | 1 |
| Blackwell, S; Caritis, SN; Esplin, MS; Grobman, WA; Iams, JD; Leveno, KJ; Mercer, BM; Rouse, DJ; Saade, GR; Sorokin, Y; Spong, CY; Thom, EA; Thorp, JM; Tita, AT; Tolosa, JE; Van Dorsten, JP; Wapner, RJ | 1 |
| Boyle, A; Driggers, RW; Feghali, M; Istwan, N; Rhea, D; Timofeev, J | 1 |
| Berghella, V; Mackeen, AD; Rafael, TJ; Zavodnick, J | 1 |
| Callaghan, WM; Damus, K; Green, NS; Howse, JL; Klebanoff, M; Lackritz, EM; Petrini, JR; Schwarz, RH | 1 |
| Delke, I; Kaunitz, AM; Sanchez-Ramos, L | 1 |
| Schindler, AE | 1 |
| Amory, J; Lawler, R; Shields, L | 1 |
| Macones, GA; Odibo, AO; Polsky, D; Stamilio, DM | 1 |
| Elovitz, MA; Mrinalini, C | 1 |
| Bailit, JL; Votruba, ME | 1 |
| Ferrara, LA; Hanley, ML; Istwan, NB; Rebarber, A; Rhea, DJ; Saltzman, DH; Stanziano, GJ | 1 |
| Brent, RL; Calda, P; Christian, MS | 1 |
| González-Quintero, VH; Hoffman, MC; Istwan, NB; Rhea, DJ; Smarkusky, L; Stanziano, GJ | 1 |
| Anderson, G; Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, F; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thom, EA; Thorp, J; Varner, M | 1 |
| Thornton, JG | 1 |
| Barton, JR; How, HY; Istwan, NB; Rhea, DJ; Stanziano, GJ | 1 |
| Cypher, R | 1 |
39 review(s) available for 17 alpha-hydroxyprogesterone caproate and Preterm Birth
| Article | Year |
|---|---|
Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic | 2022 |
Racial and ethnic representation in 17-hydroxyprogesterone caproate preterm birth prevention studies: a systematic review.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Caproates; Ethnicity; Female; Humans; Infant, Newborn; Premature Birth | 2022 |
Obstetric Indications for Progestin Therapy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2023 |
Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone | 2023 |
A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Infant, Newborn; Perinatal Death; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Randomized Controlled Trials as Topic | 2019 |
Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Stillbirth; United States; United States Food and Drug Administration | 2021 |
Next generation strategies for preventing preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Drug Approval; Drug Development; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Risk Factors | 2021 |
17 Alpha-hydroxyprogesterone caproate use in a rural state.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Medicaid; Premature Birth; Randomized Controlled Trials as Topic; Retrospective Studies | 2022 |
Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence | 2017 |
17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetrics; Pregnancy; Premature Birth; Progestins; Recurrence; Risk Assessment; Risk Factors; United States | 2017 |
Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Humans; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Rationale for current and future progestin-based therapies to prevent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervical Length Measurement; Clinical Trials as Topic; Female; Humans; Injections, Intramuscular; Pituitary Gland; Pregnancy; Premature Birth; Progestins; Uterus | 2018 |
Efficacy of progesterone for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Clinical Trials as Topic; Female; Humans; Labor, Obstetric; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins | 2018 |
Effects of progestogens in women with preterm premature rupture of membranes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic | 2019 |
Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cerclage, Cervical; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Pregnancy; Premature Birth; Secondary Prevention | 2019 |
Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Administration, Oral; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Female; Humans; Infant, Newborn; Network Meta-Analysis; Perinatal Death; Pessaries; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progesterone; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Pregnancy; Premature Birth; Progestins | 2019 |
Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Gene Expression Regulation; Humans; Hydroxyprogesterones; Metabolic Networks and Pathways; Molecular Targeted Therapy; Pregnancy; Premature Birth; Progesterone; Progestins; Receptors, Progesterone; Signal Transduction | 2014 |
The rebirth of progesterone in the prevention of preterm labor.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic | 2013 |
Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Humans; Hydroxyprogesterones; Mice; Obstetrics; Pregnancy; Premature Birth; Progesterone; Progestins; Terminology as Topic | 2013 |
Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cerclage, Cervical; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins | 2014 |
Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cervical Length Measurement; Cervix Uteri; Enterocolitis, Necrotizing; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins; Respiratory Distress Syndrome, Newborn; Treatment Outcome | 2015 |
Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Progestins | 2014 |
Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins | 2016 |
17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Triplet; Premature Birth; Progestins; Treatment Outcome | 2016 |
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Recurrence; United States | 2016 |
Vaginal Cerclage: Preoperative, Intraoperative, and Postoperative Management.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Amniocentesis; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cerclage, Cervical; Cervical Length Measurement; Device Removal; Directive Counseling; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Perioperative Care; Physical Examination; Pregnancy; Premature Birth; Prolapse; Secondary Prevention; Suture Techniques; Sutures; Uterine Cervical Incompetence | 2016 |
What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2016 |
The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins | 2017 |
Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intensive Care Units; Patient Admission; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic | 2017 |
Prematurity in twin pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Biomarkers; Cerclage, Cervical; Estrogen Antagonists; Female; Fibronectins; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Infant, Newborn; Infant, Premature; Monitoring, Ambulatory; New York; Pregnancy; Pregnancy, Multiple; Premature Birth; Prenatal Diagnosis; Risk Factors; Tocolysis; Twins; Twins, Dizygotic; Twins, Monozygotic; Ultrasonography, Prenatal | 2009 |
What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone; Progestins; Recurrence; Treatment Outcome | 2011 |
17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Humans; Hydroxyprogesterones; Premature Birth | 2011 |
17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Animals; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Recurrence; Risk Assessment; Risk Factors | 2012 |
The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Animals; Blood Glucose; Clinical Trials as Topic; Female; Fetal Death; Fetal Development; Hormone Antagonists; Humans; Hydroxyprogesterones; Immunity, Innate; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Receptors, Progesterone; Stillbirth | 2012 |
Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Confidence Intervals; Female; Follow-Up Studies; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Medroxyprogesterone Acetate; Odds Ratio; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Prenatal Care; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Treatment Outcome | 2005 |
Role of progestogens for the prevention of premature birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxypregnenolone; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Progestins; Uterus | 2005 |
Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cost Savings; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2007 |
Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Abortion, Spontaneous; Animals; Drug Compounding; Hydroxyprogesterones; Premature Birth; Progesterone Congeners; Progestins; Stillbirth | 2007 |
47 trial(s) available for 17 alpha-hydroxyprogesterone caproate and Preterm Birth
| Article | Year |
|---|---|
Comparison the efficacy of vaginal progesterone
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Caproates; Cerclage, Cervical; Enterocolitis, Necrotizing; Female; Humans; Infant, Newborn; Iran; Pregnancy; Pregnant Women; Premature Birth; Progesterone; Prospective Studies | 2022 |
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Double-Blind Method; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Pregnancy; Premature Birth; Zambia | 2021 |
Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2022 |
Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Oral; Adult; Dydrogesterone; Female; Humans; Injections, Intramuscular; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Treatment Outcome | 2022 |
Should we stop prescribing IM progesterone to women with a history of preterm labor?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; United States; United States Food and Drug Administration | 2022 |
Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Gestational Age; HIV Infections; Humans; Hydroxyprogesterones; Infant; Pregnancy; Pregnant Women; Premature Birth; Zambia | 2022 |
Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth | 2023 |
17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Female; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intramuscular; Perinatal Death; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Premature Birth; Progestins; Secondary Prevention; Treatment Failure | 2020 |
Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Injections, Intramuscular; Placenta Previa; Pregnancy; Premature Birth; Tocolytic Agents | 2020 |
Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies; United States | 2020 |
The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Infant, Low Birth Weight; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Smoking; United States | 2017 |
Racial Disparities in Delivery Gestational Age among Twin Pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Weight; Black or African American; Double-Blind Method; Female; Gestational Age; Humans; Infant; Infant Mortality; Infant, Newborn; Male; North Carolina; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Premature Birth; Prospective Studies; Survival Analysis; White People; Young Adult | 2017 |
Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Treatment Outcome; Ultrasonography, Prenatal | 2017 |
Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Logistic Models; Obesity; Pregnancy; Premature Birth; Progestins; Recurrence; Young Adult | 2018 |
A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; California; Double-Blind Method; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Time Factors; Treatment Outcome | 2018 |
Obstetric History and Likelihood of Preterm Birth of Twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Infant, Newborn; Logistic Models; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Premature Birth; Recurrence; Risk Assessment; Risk Factors; Treatment Failure; United States; Young Adult | 2018 |
A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Recurrence; Secondary Prevention; Treatment Outcome | 2018 |
PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Infant; Infant Mortality; Infant, Newborn; Injections, Intramuscular; Multicenter Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Developing Countries; Female; Gestational Age; HIV Infections; Humans; Injections, Intramuscular; Live Birth; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Stillbirth; Zambia | 2019 |
Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Treatment Outcome; Ultrasonography | 2013 |
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Recurrence | 2014 |
The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Apgar Score; Birth Weight; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Tocolysis | 2014 |
Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Female; Fibronectins; Gestational Age; Humans; Hydroxyprogesterones; Predictive Value of Tests; Pregnancy; Pregnancy, Twin; Premature Birth; Ultrasonography, Prenatal; Vagina | 2014 |
A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Injections, Intramuscular; Odds Ratio; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pregnancy, Twin; Premature Birth; Progestins; Respiratory Distress Syndrome, Newborn; Retinopathy of Prematurity; Sepsis | 2015 |
17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intention to Treat Analysis; Pregnancy; Premature Birth; Prenatal Care; Progestins; Proportional Hazards Models; Risk Factors; Treatment Outcome; Urogenital Abnormalities; Uterine Cervical Incompetence; Uterus | 2015 |
Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Hydroxyprogesterones; Obesity; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2015 |
Efficacy of midtrimester short cervix interventions is conditional on intraamniotic inflammation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Amniocentesis; Amniotic Fluid; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Cytokines; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyprogesterones; Inflammation; Interleukins; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Progestins; Proportional Hazards Models; Risk Assessment; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Prospective Studies; Tertiary Care Centers; United States; Young Adult | 2016 |
Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Decision Support Techniques; Drug Administration Schedule; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Logistic Models; Male; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Treatment Failure | 2016 |
Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prevalence; Progestins; Secondary Prevention; Smoking; Young Adult | 2016 |
17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cervical Length Measurement; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone; Prospective Studies; Suppositories; Treatment Outcome; Ultrasonography; Young Adult | 2017 |
Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Medication Adherence; Pregnancy; Premature Birth; Recurrence; Treatment Outcome; Young Adult | 2017 |
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Risk; Treatment Failure; Triplets | 2009 |
Progesterone does not prevent preterm births in women with twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Double-Blind Method; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature, Diseases; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Treatment Failure; Twins; Young Adult | 2009 |
Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dietary Supplements; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2010 |
17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervical Length Measurement; Female; Fetal Death; Humans; Hydroxyprogesterones; Infant, Newborn; Logistic Models; Multivariate Analysis; Perinatal Mortality; Pregnancy; Premature Birth; Progestins; Treatment Outcome; Uterine Cervical Incompetence; Young Adult | 2010 |
Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Placebos; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Risk Factors; Twins; Ultrasonography | 2010 |
17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Morbidity; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progestins | 2011 |
Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Treatment Outcome | 2011 |
Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Female; Gene Expression Regulation, Developmental; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Logistic Models; Multivariate Analysis; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Outcome; Premature Birth; Prospective Studies; Receptors, Progesterone; Reference Values; Risk Assessment; Secondary Prevention; Treatment Outcome | 2011 |
17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intention to Treat Analysis; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy, Multiple; Premature Birth; Progesterone Congeners | 2011 |
Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Tocolysis; Tocolytic Agents; Treatment Outcome | 2012 |
Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Biomarkers; C-Reactive Protein; Corticotropin-Releasing Hormone; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins; Treatment Outcome | 2012 |
Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Uterine Cervical Incompetence | 2012 |
17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cervical Length Measurement; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Parity; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Treatment Outcome; Young Adult | 2012 |
Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Injections, Intramuscular; Longitudinal Studies; Pregnancy; Pregnancy Outcome; Premature Birth; Prenatal Care; Probability; Reference Values; Risk Assessment; Treatment Outcome; United States | 2005 |
A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progesterone Congeners; Treatment Failure; Twins | 2007 |
142 other study(ies) available for 17 alpha-hydroxyprogesterone caproate and Preterm Birth
| Article | Year |
|---|---|
17 alpha-hydroxyprogesterone caproate, HIV, and preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Gestational Age; HIV Infections; Humans; Infant, Newborn; Premature Birth | 2021 |
Revisiting the placental clock: Early corticotrophin-releasing hormone rise in recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Area Under Curve; Cohort Studies; Corticotropin-Releasing Hormone; Enzyme-Linked Immunosorbent Assay; Female; Gestational Age; Humans; Placenta; Pregnancy; Pregnancy Outcome; Premature Birth; Prenatal Care; Prospective Studies; Radioimmunoassay; Risk Factors; ROC Curve; Up-Regulation | 2021 |
A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Pregnancy; Premature Birth; Tumor Necrosis Factor-alpha | 2023 |
Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Medicaid; Pregnancy; Premature Birth; Retrospective Studies | 2023 |
Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins | 2022 |
A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Retrospective Studies | 2023 |
Regarding 'Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth'.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth; Progestins | 2022 |
Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Fetal Membranes, Premature Rupture; Humans; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP).
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Immune effects of 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Premature Birth; Progestins | 2022 |
Effect of formulation and route of administration on the distribution of 17-hydroxyprogesterone caproate in rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Animals; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth; Rats; Rats, Sprague-Dawley | 2023 |
FDA Revokes Approval for Preterm Birth Drug Makena.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Recalls; Female; Humans; Infant, Newborn; Premature Birth; Reproductive Control Agents; United States; United States Food and Drug Administration | 2023 |
Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Perinatology; Pregnancy; Premature Birth; Progesterone; United States; United States Food and Drug Administration | 2023 |
Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cholestasis, Intrahepatic; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2023 |
Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pharmaceutical Preparations; Pregnancy; Premature Birth; Rare Diseases; United States | 2023 |
Discontinuation Of Long-Established Hydroxyprogesterone Caproate; Call For Awareness And Drug-Substitutes: A Letter To The Editor.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Premature Birth | 2023 |
The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Progestins; Retrospective Studies; Treatment Failure | 2020 |
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Conflict of Interest; Drug and Narcotic Control; Drug Industry; Female; Fetal Death; Humans; Infant, Newborn; Obstetrics; Perinatal Death; Pregnancy; Premature Birth; Progestins; Research Design; Societies, Medical; Treatment Failure; United States; United States Food and Drug Administration | 2020 |
SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins; Recurrence | 2020 |
Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Drug Approval; Female; Humans; Infant, Newborn; Perinatal Mortality; Pregnancy; Premature Birth; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Drug Labeling; Female; Humans; Infant, Newborn; Pharmaceutical Services; Pregnancy; Premature Birth; Recurrence; United States; United States Food and Drug Administration | 2020 |
Re-examining the Meis Trial for Evidence of False-Positive Results.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2020 |
The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Postpartum Hemorrhage; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2019 |
A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug and Narcotic Control; Drug Approval; Evidence-Based Medicine; Female; Humans; Observational Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Recurrence; United States; United States Food and Drug Administration | 2021 |
Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Advisory Committees; Black People; Clinical Trials as Topic; Drug Approval; Europe; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Product Recalls and Withdrawals; Progestins; Risk Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Black or African American; Clinical Trials as Topic; Drug Approval; Female; Health Status Disparities; Humans; Pregnancy; Premature Birth; Progestins; Risk Factors; United States; United States Food and Drug Administration | 2020 |
Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy, Twin; Premature Birth; Prospective Studies; Randomized Controlled Trials as Topic | 2022 |
Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Prospective Studies; Retrospective Studies | 2020 |
Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2020 |
Delivering equity: preterm birth by socioeconomic class before and after coverage of 17-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth; Retrospective Studies; Socioeconomic Factors; United States | 2022 |
Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Nanomedicine; Pharmaceutical Preparations; Pregnancy; Premature Birth; Progesterone; Progestins | 2021 |
17-hydroxyprogesterone caproate for women with congenital uterine anomalies: does it impact the risk of recurrent preterm birth?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Urogenital Abnormalities; Uterus | 2021 |
17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Venous Thromboembolism | 2022 |
Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Computer Communication Networks; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Live Birth; Pregnancy; Premature Birth; Progesterone; United States | 2022 |
Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hypertension; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; United States | 2021 |
Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2021 |
Performance on a modified signal detection task of attention is impaired in male and female rats following developmental exposure to the synthetic progestin, 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Animals; Attention; Female; Humans; Male; Pregnancy; Premature Birth; Progestins; Rats | 2021 |
Developmental exposure to the synthetic progestin, 17α-hydroxyprogesterone caproate, disrupts the mesocortical serotonin pathway and alters impulsive decision-making in rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Animals; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Rats; Reward; Serotonin | 2021 |
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2017 |
The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cytochrome P-450 CYP3A; Female; Gestational Age; Humans; Hydroxyprogesterones; Polymorphism, Single Nucleotide; Pregnancy; Premature Birth; Progestins; Receptors, Progesterone | 2017 |
Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cohort Studies; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Leukomalacia, Periventricular; Male; North Carolina; Pregnancy; Premature Birth; Progestins; Recurrence; Retrospective Studies | 2017 |
Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Female; Gestational Age; Humans; Hydroxyprogesterones; Medication Adherence; Pregnancy; Premature Birth; Retrospective Studies; Young Adult | 2017 |
Adjuvant administration of 17-α-hydroxy-progesterone caproate in women with three or more second trimester pregnancy losses undergoing cervical cerclage is no more effective than cerclage alone.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cohort Studies; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Premature Birth; Retrospective Studies; United States; Uterine Cervical Incompetence | 2018 |
Personalised medicine-the potential yet realised.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Case-Control Studies; Female; Humans; Pharmacogenetics; Precision Medicine; Pregnancy; Premature Birth | 2018 |
Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Cutaneous; Administration, Rectal; Animals; Drug Administration Schedule; Drug Carriers; Female; Hydroxyprogesterones; Injections, Subcutaneous; Pregnancy; Premature Birth; Progesterone; Progestins; Rats; Treatment Outcome | 2017 |
Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cohort Studies; Cost-Benefit Analysis; Drug Utilization Review; Female; Gestational Age; Humans; Hydroxyprogesterones; Massachusetts; Medicaid; Medication Adherence; Pregnancy; Pregnancy Outcome; Premature Birth; Progesterone; Retrospective Studies; United States; Young Adult | 2017 |
Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Databases, Factual; Drug Costs; Drug Utilization; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2017 |
In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Extraembryonic Membranes; Female; Fetal Membranes, Premature Rupture; Granulocyte-Macrophage Colony-Stimulating Factor; Hemostatics; Humans; Hydroxyprogesterones; In Vitro Techniques; Models, Biological; Pregnancy; Premature Birth; Progestins; Thrombin; Tumor Necrosis Factor-alpha | 2017 |
Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Costs; Estrogen Antagonists; Female; Health Services Accessibility; Healthcare Disparities; Humans; Hydroxyprogesterones; Louisiana; Medicaid; Needs Assessment; Orphan Drug Production; Pregnancy; Pregnancy, High-Risk; Premature Birth; Quality Improvement; United States; United States Food and Drug Administration | 2017 |
Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Fluids; Cervix Uteri; Cytokines; Female; Gestational Age; Humans; Matrix Metalloproteinases; Parity; Pregnancy; Premature Birth; Prospective Studies; United States; Young Adult | 2018 |
Limitations of cohort studies with historic controls.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Prospective Studies | 2018 |
Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Case-Control Studies; CpG Islands; Epigenesis, Genetic; Estrogen Antagonists; Female; Gene Expression; Gestational Age; Humans; Infant, Newborn; Methylation; Nitric Oxide; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Signal Transduction | 2018 |
Response to 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Prospective Studies | 2018 |
Reply.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Prospective Studies | 2018 |
Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; District of Columbia; Female; Healthcare Disparities; Humans; Hydroxyprogesterones; Infant, Newborn; Medicaid; Mothers; Pregnancy; Premature Birth; Prenatal Care; Puerto Rico; Socioeconomic Factors; United States | 2018 |
Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Reducing Barriers to 17-Hydroxprogestrone Caproate (17P) Injections to Prevent Recurrent Preterm Birth in Mississippi.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Education, Medical; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Mississippi; Pregnancy; Premature Birth; Progestins; Recurrence | 2016 |
Barriers and Facilitators to Recurrent Preterm Birth Prevention among Low-Income Women: A Qualitative Study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Attitude to Health; Female; Health Status Disparities; Humans; Injections, Intramuscular; Patient Satisfaction; Physician-Patient Relations; Poverty; Pregnancy; Premature Birth; Recurrence; Risk Factors; Secondary Prevention | 2019 |
Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Healthcare Disparities; Humans; Insurance Coverage; Insurance, Health; Linear Models; Massachusetts; Pregnancy; Premature Birth; Progestins; Racial Groups; Retrospective Studies | 2019 |
Reply.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Prospective Studies | 2019 |
Progesterone for preterm birth prevention: the importance of informed consent.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Infant, Newborn; Informed Consent; Pregnancy; Premature Birth; Progesterone; Progestins; Prospective Studies | 2019 |
Progesterone effects on vaginal cytokines in women with a history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adolescent; Adult; Female; Gene Expression Regulation; Gestational Age; Humans; Immunity, Innate; Infant, Newborn; Interleukin-13; Interleukin-1alpha; Interleukin-1beta; Interleukin-2; Pregnancy; Premature Birth; Progesterone; Progestins; Prospective Studies; Vagina | 2018 |
Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Age Factors; Bayes Theorem; Cohort Studies; Ethnicity; Female; Geography; Humans; Infant, Newborn; Insurance, Health; Pregnancy; Premature Birth; Prenatal Care; Racial Groups; Retrospective Studies; Risk Factors; Secondary Prevention; Smoking; United States | 2019 |
Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Guideline Adherence; Hispanic or Latino; Humans; Medication Adherence; Practice Guidelines as Topic; Pregnancy; Premature Birth; Prenatal Care; Progestins; Retrospective Studies | 2020 |
Defining 17OHP-C responsiveness.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Pregnancy; Premature Birth | 2019 |
Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Recurrence | 2021 |
Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Drug Administration Schedule; Estrogen Antagonists; Female; Gestational Age; Humans; Medication Adherence; Middle Aged; Obstetric Labor, Premature; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Recurrence; Retrospective Studies; Young Adult | 2019 |
17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth | 2013 |
17 OHPC for prevention of preterm birth in twins: back to the drawing board?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Ultrasonography | 2013 |
Prevention of preterm birth by progestational agents: what are the molecular mechanisms?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Animals; Cervix Uteri; Connexin 43; Cyclooxygenase 2; Female; Homeodomain Proteins; Hydroxyprogesterones; Kruppel-Like Transcription Factors; Mice; MicroRNAs; Pregnancy; Premature Birth; Progesterone; Receptors, Oxytocin; STAT5 Transcription Factor; Uterine Contraction; Uterus; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Compounding; Drug Contamination; Drug Stability; Endotoxins; Humans; Hydroxyprogesterones; Premature Birth; Preservatives, Pharmaceutical; Pyrogens; Time Factors; United States; United States Food and Drug Administration | 2013 |
Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Black or African American; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, High-Risk; Premature Birth; Retrospective Studies; Secondary Prevention; White People; Young Adult | 2014 |
Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Female; Humans; Hydroxyprogesterones; Legislation, Drug; Obstetrics; Patient Safety; Pregnancy; Premature Birth; Progesterone Congeners; Progestins; United States; United States Food and Drug Administration | 2013 |
The effect of intramuscular progesterone on the rate of cervical shortening.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2013 |
Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Ohio; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2014 |
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Case-Control Studies; Estrogen Antagonists; Exome; Female; Genetic Variation; Humans; Hydroxyprogesterones; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pharmacogenetics; Pregnancy; Premature Birth; Prospective Studies; Secondary Prevention; Sequence Analysis, DNA | 2014 |
There is still insufficient data to recommend screening twin pregnancies with transvaginal ultrasound cervical length, but this might change soon!
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins | 2015 |
Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins | 2015 |
Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Diabetes, Gestational; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Maternal Age; Obesity; Pregnancy; Premature Birth; Retrospective Studies; Risk Factors; Tocolytic Agents; United States | 2014 |
Why the United States preterm birth rate is declining.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adolescent; Adult; Cerclage, Cervical; Cervical Length Measurement; Evidence-Based Medicine; Female; Humans; Hydroxyprogesterones; Practice Guidelines as Topic; Pregnancy; Pregnancy in Adolescence; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Recurrence; Smoke-Free Policy; United States; Young Adult | 2015 |
Progestogen safety in multiple gestations: application of the Bradford Hill criteria.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adverse Drug Reaction Reporting Systems; Evidence-Based Medicine; Female; Humans; Hydroxyprogesterones; Meta-Analysis as Topic; Observational Studies as Topic; Pregnancy; Pregnancy, Multiple; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2015 |
17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Administration Schedule; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Infant, Newborn; Insurance Coverage; Louisiana; Medicaid; Patient Protection and Affordable Care Act; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Reimbursement, Incentive; United States | 2015 |
Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxyprogesterones; Obesity; Overweight; Pregnancy; Pregnancy Complications; Premature Birth; Progestins; Recurrence; Retrospective Studies; Young Adult | 2015 |
Relationship between interpregnancy interval and cervical length in high-risk women.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Intervals; Cerclage, Cervical; Cervical Length Measurement; Female; Gestational Age; Humans; Hydroxyprogesterones; Linear Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2016 |
Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Chorioamnionitis; Cohort Studies; Endometritis; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Logistic Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk Factors; Sepsis; Treatment Outcome | 2015 |
Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Animals; Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cervix Uteri; Decidua; Endotoxins; Escherichia coli; Female; Forkhead Transcription Factors; Hydroxyprogesterones; Interferon-gamma; Interleukin-1beta; Interleukin-2 Receptor alpha Subunit; Macrophages; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Monocytes; Myometrium; Neutrophils; Pregnancy; Premature Birth; Progesterone; Progesterone Congeners | 2015 |
Use of hydroxyprogesterone caproate to prevent preterm labour in uterine didelphys: a case report.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Urogenital Abnormalities; Uterus | 2016 |
Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abruptio Placentae; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Longitudinal Studies; Pregnancy; Pregnancy, High-Risk; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Treatment Failure; Uterine Hemorrhage; Young Adult | 2016 |
17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; North Carolina; Pregnancy; Premature Birth; Recurrence; Reproductive Control Agents; Retrospective Studies; Young Adult | 2016 |
Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Asian; Black or African American; Directive Counseling; Estrogen Antagonists; Female; Healthcare Disparities; Hispanic or Latino; Humans; Hydroxyprogesterones; Illinois; Insurance, Health; Medicaid; Medication Adherence; Middle Aged; Pregnancy; Premature Birth; Retrospective Studies; United States; White People; Young Adult | 2016 |
17-α Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth: One Size May Not Fit All.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Obstetrics; Practice Patterns, Physicians'; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Prenatal Care; United States | 2016 |
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Estrogen Antagonists; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Medication Adherence; Patient Selection; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Secondary Prevention | 2016 |
Appropriate Use of Progesterone to Prevent Preterm Birth: Approaches to Measurement for Driving Improvement.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Infant, Newborn; Medicaid; Outcome Assessment, Health Care; Pregnancy; Premature Birth; Surveys and Questionnaires; United States | 2017 |
Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Humans; Hydroxyprogesterones; Premature Birth; Progestins | 2017 |
The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prenatal Care; Progestins; Recurrence; Risk Factors; Secondary Prevention | 2017 |
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Analysis of Variance; Case-Control Studies; Exome Sequencing; Female; Gestational Age; Humans; Pharmacogenetics; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Recurrence; United States | 2018 |
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cohort Studies; Diabetes, Gestational; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins; Secondary Prevention | 2008 |
The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prospective Studies; Secondary Prevention; Tocolytic Agents; Young Adult | 2008 |
Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Ambulatory Care; Female; Fetal Monitoring; Hospitalization; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention | 2008 |
Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Biomarkers, Pharmacological; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone Congeners; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Uterine Contraction | 2010 |
The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Premature Birth; Progestins; Young Adult | 2009 |
Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Cytochrome P-450 CYP3A; Estrogen Antagonists; Female; Fetus; Hepatocytes; Humans; Hydroxyprogesterones; Insecta; Kinetics; Microsomes; Pregnancy; Premature Birth; Transfection | 2010 |
Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cohort Studies; Female; Home Care Services; Humans; Hydroxyprogesterones; Injections, Intramuscular; Obstetric Labor, Premature; Patient Education as Topic; Patient Satisfaction; Pregnancy; Premature Birth; Prenatal Care; Progestins; Young Adult | 2010 |
17-alpha-hydroprogesterone caproate and cervical changes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Patient Selection; Pregnancy; Premature Birth; Progestins | 2010 |
Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chi-Square Distribution; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Injections, Intramuscular; Longitudinal Studies; Managed Care Programs; Medicaid; Multicenter Studies as Topic; National Institute of Child Health and Human Development (U.S.); Patient Compliance; Pregnancy; Premature Birth; Randomized Controlled Trials as Topic; Risk Factors; United States; United States Food and Drug Administration | 2010 |
Intramuscular 17α-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Gestational Age; Humans; Hydroxyprogesterones; Immunomodulation; Immunosuppression Therapy; In Vitro Techniques; Injections, Intramuscular; Interleukin-6; Leukocytes, Mononuclear; Pregnancy; Premature Birth; Reference Values | 2010 |
17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Decision Support Techniques; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone | 2011 |
The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Kaplan-Meier Estimate; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention; Ultrasonography; Uterine Cervical Incompetence | 2011 |
Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Drug Costs; Female; Health Care Costs; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Patents as Topic; Pregnancy; Premature Birth; United States; United States Food and Drug Administration | 2011 |
Deus ex Makena?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins | 2011 |
Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Female; Health Care Costs; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; United States; United States Food and Drug Administration | 2011 |
Trends in prematurity: what do changes at an urban institution suggest about the public health impact of 17-alpha hydroxyprogesterone caproate?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cross-Sectional Studies; Delivery, Obstetric; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Infant, Premature; Logistic Models; Male; Pregnancy; Premature Birth; Progestins; Public Health; Secondary Prevention; Urban Population | 2012 |
Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Half-Life; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Triplet; Pregnancy, Twin; Premature Birth; Progestins; Randomized Controlled Trials as Topic | 2011 |
The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Blood Glucose; Diabetes, Gestational; Dose-Response Relationship, Drug; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxyprogesterones; Logistic Models; Obesity; Pregnancy; Premature Birth; Progestins; Prospective Studies; Secondary Prevention; Young Adult | 2011 |
What is in a name? A higher cost!
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Compounding; Drug Industry; Humans; Hydroxyprogesterones; Orphan Drug Production; Premature Birth; Progesterone Congeners; Terminology as Topic | 2011 |
The influence of prior obstetrical history on current 17-hydroxyprogesterone caproate use.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Patient Acceptance of Health Care; Practice Patterns, Physicians'; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention; Term Birth; Treatment Refusal; Young Adult | 2011 |
Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Logistic Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome; United States | 2012 |
17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk; Secondary Prevention; Term Birth | 2011 |
Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Age Factors; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Pregnancy; Premature Birth; Progestins; Secondary Prevention | 2011 |
17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Prenatal Care; United States; United States Food and Drug Administration; Women's Health | 2012 |
Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Female; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Progestins; Quality Control; United States; United States Food and Drug Administration | 2012 |
Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Female; Gestational Age; Guideline Adherence; Home Care Services; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Medicaid; Medication Adherence; Practice Guidelines as Topic; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Retrospective Studies; United States | 2012 |
Studies examine fetal surgery trade-offs, drug interactions, and uterine rupture.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Child Development; Drug Interactions; Dystocia; Female; Fetal Diseases; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Meningomyelocele; Pregnancy; Pregnancy Complications; Premature Birth; Prenatal Diagnosis; Progestins; Risk; Uterine Rupture; Vaginal Birth after Cesarean | 2012 |
Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Packaging; Female; Fetal Death; Home Care Services; Humans; Hydroxyprogesterones; Infant Mortality; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins | 2012 |
The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Biomarkers; Cervical Length Measurement; Cohort Studies; Decision Support Techniques; Female; Fibronectins; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Recurrence; Regression Analysis; Retrospective Studies; Sensitivity and Specificity | 2012 |
Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Multicenter Studies as Topic; Pregnancy; Pregnancy, High-Risk; Premature Birth; Randomized Controlled Trials as Topic; Retrospective Studies; Uterine Cervical Incompetence; Young Adult | 2012 |
Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obesity; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone Congeners; Recurrence; Retrospective Studies; Young Adult | 2013 |
Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Weight; Cerclage, Cervical; Cervical Length Measurement; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Time Factors; Uterine Cervical Incompetence | 2013 |
Hydroxyprogesterone caproate and progesterone increase tumor necrosis factor-alpha production in lipopolysaccharide stimulated whole blood from non-pregnant women.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; In Vitro Techniques; Lipopolysaccharides; Pregnancy; Premature Birth; Progesterone; Tumor Necrosis Factor-alpha | 2005 |
17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cost-Benefit Analysis; Decision Support Techniques; Female; Gestational Age; Health Care Costs; Hospitalization; Humans; Hydroxyprogesterones; Multivariate Analysis; Obstetric Labor Complications; Obstetric Labor, Premature; Parity; Pregnancy; Premature Birth; Progestins; Risk Factors; Secondary Prevention; United States | 2006 |
The use of progestational agents for preterm birth: lessons from a mouse model.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; C-Reactive Protein; Female; Hydroxyprogesterones; Interleukin-10; Interleukin-6; Lipopolysaccharides; Medroxyprogesterone Acetate; Mice; Models, Animal; Pregnancy; Premature Birth; Progestins | 2006 |
17 Progesterone for preterm birth prevention: a potential 2 billion dollar opportunity.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Costs and Cost Analysis; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2007 |
Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Adult; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Retrospective Studies | 2007 |
Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone Congeners; Retrospective Studies; Secondary Prevention | 2007 |
Reducing preterm births.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Multicenter Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic | 2007 |
Progesterone and preterm labor--still no definite answers.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progesterone; Twins | 2007 |
Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Recurrence; Retrospective Studies; Tocolytic Agents; Treatment Outcome | 2007 |
Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Premature Birth; Recurrence; Residence Characteristics; Retrospective Studies; Tocolytic Agents | 2007 |
Gestiva for preventing prematurity: a new view of an old therapy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2007 |
Progesterone and preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Research Design; Risk Factors; Twins; Ultrasonography | 2007 |